Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 7/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 4/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6546991 | 1.00 | FAAH (0.42) | FAAHCA1CNR2CA2CA12 | |
| SCHEMBL6546923 | 0.98 | CA1 (0.43) | FAAHCA1CNR2CA2CA12 | |
| SCHEMBL6546400 | 0.92 | CA1 (0.44) | FAAHCA1CNR2CA2CA12 | |
| SCHEMBL7864572 | 0.88 | FAAH (0.48) | FAAHCA1CNR2CA2CA12 | |
| SCHEMBL27905197 | 0.86 | CA1 (0.50) | FAAHCA1CNR2CA2CA12 | |
| SCHEMBL6546429 | 0.85 | CA1 (0.41) | FAAHCA1CNR2CA2CA12 | |
| SCHEMBL14229342 | 0.84 | CNR2 (0.45) | FAAHCA1CNR2CA2CA12 | |
| SCHEMBL14229917 | 0.84 | CNR2 (0.45) | FAAHCA1CNR2CA2CA12 | |
| SCHEMBL6546815 | 0.84 | CNR2 (0.42) | FAAHCA1CNR2CA2CA12 | |
| SCHEMBL6546381 | 0.84 | FAAH (0.40) | FAAHCNR2CA2CES1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379238-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | Abbott Laboratories (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030092757-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | ABBOTT LABORATORIES | 2003-05-15 | — | — | US | disclosed |
| WO-2002085351-A1 | FAVORABLE MODULATION OF HEALTH-RELATED QUALITY OF LIFE AND HEALTH-RELATED QUALITY-ADJUSTED TIME-TO-PROGRESSION OF DISEASE IN PATIENTS WITH PROSTATE CANCER | ABBOTT LABORATORIES (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092757-A1 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | KLK3, ACP3, BPHL | FAAH 1986/4885CA1 4501/4885CNR2 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.